The Algerian National Agency for Pharmaceutical Products (ANPP) has issued a warning about a fake medication being sold in the country's market. The medication in question is "DYSPORT", a botulinum toxin type A product allegedly manufactured by British company "Biopharm". However, the ANPP stated that all indications suggest that the product is counterfeit.
The fake medication is a powder for injection solution, with a dosage of 500 units. The product's packaging bears the batch number S05061, an expiration date of 02/2028, and the serial number DYN7PCXH84UNBF. The ANPP has advised healthcare professionals and the general public to exercise extreme caution when it comes to obtaining, possessing, and using this product.
According to the ANPP, the counterfeit DYSPORT product has been linked to serious side effects. The agency has taken swift action to alert healthcare professionals and the public about the potential risks associated with this fake medication. The use of this product is strictly limited to hospital settings, as stipulated in the registration decision.
The ANPP has identified that the batch of botulinum toxin in question was not manufactured by the UK-based company "Ipsen". This has raised concerns about the authenticity and safety of the product. As a result, the agency has urged caution, particularly among healthcare professionals involved in clinical practice.
The Algerian authorities have emphasized that the safety and efficacy of medications are of utmost importance. The ANPP has taken measures to protect public health by issuing warnings and advising against the use of counterfeit products. The agency is working to prevent the distribution of fake medications and ensure that only authorized and safe products are available in the market.
The incident highlights the need for vigilance in the pharmaceutical industry. Counterfeit medications can have severe consequences for public health, and it is essential for regulatory agencies to work closely with manufacturers and healthcare professionals to prevent such incidents. The Algerian authorities have demonstrated their commitment to ensuring the safety and quality of medications available in the country.
The warning issued by the ANPP serves as a reminder to healthcare professionals and the public to be cautious when using medications. It is crucial to verify the authenticity and safety of products before use. The agency will continue to monitor the situation and take necessary actions to protect public health.
Key points
- The Algerian National Agency for Pharmaceutical Products warns of a fake botulinum toxin medication, DYSPORT, being sold in the market.
- The counterfeit product has been linked to serious side effects and is strictly limited to hospital settings.
- The agency has advised caution and verified that the batch in question was not manufactured by the UK-based company Ipsen.
